UBS analyst Trung Huynh raised the firm’s price target on Regeneron (REGN) to $584 from $560 and keeps a Neutral rating on the shares. UBS is 2% above consensus for Q2 financials, driven by positive expectations for the Eylea franchise, the analyst tells investors in a research note. The firm views current valuation as fairly reflecting the mixed risk/rewards in near-term.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Regeneron Advances in Lung Cancer Immunotherapy with New Clinical Study
- Regeneron’s Latest Melanoma Study: A Potential Game-Changer?
- Regeneron’s Phase 3 Trial: A New Hope for Lymphoma Treatment?
- Regeneron and Sanofi’s Dupilumab Study: A Potential Breakthrough for Lichen Simplex Chronicus
- Regeneron price target lowered to $754 from $755 at Morgan Stanley